Adlai Nortye Ltd. (NASDAQ:ANL – Get Free Report) was the recipient of a large decline in short interest in February. As of February 15th, there was short interest totalling 3,800 shares, a decline of 13.6% from the January 31st total of 4,400 shares. Based on an average trading volume of 9,100 shares, the short-interest ratio is currently 0.4 days.
Adlai Nortye Trading Down 4.3 %
Shares of ANL stock opened at $2.20 on Wednesday. The company’s fifty day moving average price is $2.17 and its two-hundred day moving average price is $2.28. Adlai Nortye has a 12 month low of $1.85 and a 12 month high of $17.48.
Analyst Upgrades and Downgrades
Separately, HC Wainwright reiterated a “buy” rating and set a $9.00 price objective on shares of Adlai Nortye in a research note on Monday, November 11th.
Adlai Nortye Company Profile
Adlai Nortye Ltd., a clinical-stage biotechnology company, focuses on the discovery and development of cancer therapies in the United States and Mainland China. Its lead product is AN2025, a pan-phosphoinositide 3-kinase inhibitor, which is in Phase III clinical trial for the treatment of recurrent or metastatic head and neck squamous cell carcinomas.
Featured Articles
- Five stocks we like better than Adlai Nortye
- Why Invest in 5G? How to Invest in 5G Stocks
- GitLab: Get In While It’s Down—Big Rebound Ahead
- How to Effectively Use the MarketBeat Ratings Screener
- Tesla Stock: Finding a Bottom May Take Time
- How to Invest in Small Cap Stocks
- Duolingo: This Beaten-Down Stock Is About to Rally 38%
Receive News & Ratings for Adlai Nortye Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adlai Nortye and related companies with MarketBeat.com's FREE daily email newsletter.
